[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$605625m
The crypto market is experiencing significant volatility following recent regulatory news. Investors are closely watching for further developments and their impact on asset prices.
About $605625m
This refers to a specific cryptocurrency or digital asset, likely with a ticker symbol or unique identifier.
Engagements: XXXXXX #
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXXX
Daily Average: XXXXX
1 Month: XXXXXX +1,481,000%
6 Months: XXXXXX +4,843%
1-Year High: XXXXXX on 2025-11-05
1-Year Low: X on 2025-09-07
| Social Network | X |
|---|---|
| Engagements | XXXXXX |
Mentions: X #
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
6 Months: X +33%
1-Year High: X on 2025-11-05
1-Year Low: X on 2025-08-31
| Social Network | X |
|---|---|
| Mentions | XXX |
Creators: X #
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $605625m in the last XX hours which is up XX% from X in the previous XX hours
Daily Average: X
6 Months: X +350%
1-Year High: X on 2025-11-05
1-Year Low: X on 2025-08-31
Top assets mentioned In the posts about $605625m in the last XX hours
Hims & Hers Health, Inc. (HIMS) Hims & Hers Health, Inc. (HIMS)
Top topics mentioned In the posts about $605625m in the last XX hours
stocks consumer defensive, $hims, hims hers, $599m, $68m, $784m, $23352355b, $6296m, $600m, $794m, cash flow, $5565m, $5799m, $58024m, $59898m, $6297m, $58037m, $novcde, $756m, $63169m, $2342b, weight loss, $2025m, $545m, tax bracket, just got, $1b, $16m, $78m
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Based on Hims & Hers' Q3 2025 earnings Q3 revenue hit $600M (up XX% QoQ from Q2's $545M). Q4 guidance of $605-625M implies 1-4% QoQ growth. Key reasons: $20-25M headwind from sterile weight loss fulfillment changes (shorter cadences lower revenue per shipment) product transitions to personalized options price cuts on GLP-1 and investments in expansions. Expected to normalize in 2026not mainly seasonal"
X Link @grok 2025-11-04T09:04Z 6.6M followers, XX engagements
"$HIMS Just got home and didnt get to listen in on earnings. Heres my initial thought on the numbers: - Killed revenue - Miss on eps but was due to one time tax loss benefit in 2024 not longer existing this year - Beat EBITDA estimate - revenue guidance was not lowered but narrowed. Still within the same range as companys guide last quarter. - narrowed EBITDA guidance Overall not a bad quarter at all at least much better than the price action would suggest. Perhaps the street is still waiting on $NVO earning call to clear the water on the potential new partnership. If $NVO confirms the ongoing"
X Link @investwithsheng 2025-11-04T06:12Z 4826 followers, 5804 engagements
"$HIMS Q3 '25: Revenue $599M (beat +49% YoY) subs 2.5M (+21%) EBITDA $78M (+53%). EPS $XXXX miss vs $XXXX net income $16M (down big from one-off). Guidance: FY rev $2.3352.355B Q4 $605625M (soft vs street). Hers $1B+ '26 + Novo in the works Just imagine what happens with peptides in the next XX months 👀"
X Link @BoujeeFinances 2025-11-04T03:31Z 9442 followers, 1331 engagements
"$HIMS Hims & Hers Health Q3 2025 Earnings Summary Q3 Results: EPS: $XXXX miss by $XXXX (vs. $XXXX consensus) Revenue: $598.98M up XXXX% YoY beat vs. $580.24M consensus Guidance: Q4 Revenue: $605625M (below $631.69M consensus) Q4 Adj. EBITDA: $5565M Strategic Update: Novo Nordisk Partnership Talks: Hims & Hers is in active discussions with Novo Nordisk to make Wegovy injections and oral Wegovy (pending FDA approval) available via its platform. The collaboration aims to expand consumer access to GLP-1 treatments under prescriber guidance. The company clarified that no definitive agreement has"
X Link @tenet_research 2025-11-03T21:12Z 452.1K followers, 1233 engagements